The Future of ‘Femtech’

Company Overview and Scale

• Flow Health, led by CEO Anne Roberts, operates as the world's leading health app for women's reproductive cycles, serving 190 million users and 1.4 million premium subscribers.
• Ava, co-founded by Leah Von Bitter, utilizes a wearable device and app to measure physiological data (including heart rate variability and perfusion) at a volume of one million data points nightly to detect fertile windows.
• Chiron Medical, founded by Peter Ketch-Kometi, focuses on using machine learning to assist radiologists in detecting and tracking breast cancer, addressing a global screening challenge where two radiologists often review every scan.

Definition and Positioning of "Femtech"

• Leah Von Bitter describes the "Femtech" label as a double-edged sword: while it has successfully attracted analyst and investor attention, she prefers positioning Ava strictly as a regulated healthcare company rather than a tech startup.
• Anne Roberts defines Femtech as technology serving women's health needs from menstruation to menopause, arguing that the distinction between "medical" and "lifestyle" products is artificial and that the industry must bridge this gap with evidence-based science.
• Peter Ketch-Kometi asserts that while Chiron is a healthcare company, breast cancer screening is a definitive "Femtech" area due to its anatomical specificity, noting the sector is vital for safeguarding successful screening programs currently under stress.

Regulatory Strategy and Compliance

• Peter Ketch-Kometi highlights the need to shift regulatory frameworks to accommodate AI, emphasizing that AI enables large-scale clinical trials and that "generalizability" is synonymous with patient safety.
• Leah Von Bitter contrasts the unregulated cycle-tracking algorithms common in consumer wearables (which use simple logic) with Ava's complex, regulated algorithms that require rigorous clinical evidence.
• Leah notes Ava's strategic choice to pursue regulation to enable reimbursement by payers and sales through providers, stating, "if you want to build the very best product, you're regulated."
• Anne Roberts clarifies that while Flow currently lacks FDA approval for non-diagnostic features, it collaborates with over 80 medical advisors and universities to ensure safety; future regulatory submission depends on developing diagnostic features like risk-assessment chatbots.

Investment Landscape and Monetization

• Antonia Riera notes that while global tech investment is record-high, Femtech has yet to see large-scale exits or IPOs comparable to Fintech, though this is expected to evolve over time.
• Anne Roberts reports that Flow Health revenues increased by over 107% in the last four months, with active subscribers growing 4x year-over-year, demonstrating sustainable growth potential despite investment skepticism.
• Peter Ketch-Kometi identifies the primary barrier to scaling deep-tech healthcare solutions as the availability of long-term growth capital, though he observes that demand for AI-driven clinical evidence is currently attracting necessary funding.

Technical Applications and Data Utility

• Leah Von Bitter reveals that Ava's deep understanding of female baseline physiology, initially developed for fertility, was applied to create an algorithm for early COVID detection, avoiding false positives caused by hormonal fluctuations that confuse other wearables.
• Ava is currently conducting a large-scale trial in the Netherlands with 20,000 participants to validate its COVID detection algorithm, proving the versatility of their physiological data platform.
• Peter Ketch-Kometi indicates that while Chiron has nearly solved problems in breast cancer screening, they have early successes expanding their AI platform to other cancer types and anatomical locations.

Market Expansion and Future Roadmaps

• Flow Health plans to expand its total addressable market by engaging the "other half of the world" (men and partners) to normalize conversation around female health and turn cycle tracking into a shared experience.
• Ava intends to expand its product portfolio into contraception, pregnancy, and menopause, leveraging its massive dataset to build continuous applications that improve women's daily lives.
• Chiron aims to reduce the fear associated with cancer diagnoses by introducing reliable, modern AI into clinical practice, potentially breaking down historical barriers in hospital technology adoption.
• Antonia Riera identifies the pandemic as a critical catalyst that forced medical practitioners and governments to adopt digital tools, creating a long-term trend for technology integration in healthcare driven by aging populations and rising costs.